Shares of GW Pharmaceuticals PLC /zigman2/quotes/209686240/composite GWPH +0.94% fell 0.4% in premarket trading, after Stifel Nicolaus analyst Paul Matteis downgraded the maker of the cannabis-derived epilepsy drug Epidiolex, citing disappointing physician feedback regarding "off-label" use of the drug. Matteis cut his rating to hold after being at buy for at least the past two years, and cut his stock price target to $140 from $150. Matteis stressed that the downgrade wasn't a call on GW's second quarter results, which are expected in early August, as he thinks the company will beat expectations as the impact of COVID-19 doesn't seem as bad as projected. "Instead, what's led to a change in our view is conservative physician expectations for Epidiolex use in 'off-label' refractory epilepsy, whereas we believe substantial uptake here is: 1) key to the bull case; and 2) necessary to meet or beat 2021-2025 consensus sales projections," Matteis wrote in a note to clients. The stock has run up 40.3% over the past three months through Tuesday, while the Cannabis ETF /zigman2/quotes/213173823/composite THCX +2.30% has climbed 22.5% and the S&P 500 /zigman2/quotes/210599714/realtime SPX +1.05% has advanced 14.9%.